TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be outpatients who are aged 6 to 18 years old at the initial screening visit.~* Patients must have ADHD, based on the accepted criteria for that disease~* Patients must not have taken any medication used to treat ADHD for at least two weeks prior to beginning study treatment; and at least one week prior to the study screening visit during which initial ADHD assessments were made~* Patients must be able to swallow capsules~* Patients and parents (or legal guardians) must be judged by the study investigator to be reliable to keep appointments for clinic visits and all tests, including blood tests and any other required examinations~Exclusion Criteria:~* Patients must not have received any treatment within the last 30 days with a drug that has not been approved by their country's appropriate government agency~* Patients will not be included in the study if they have previously experienced any unwanted effects or serious medical events during atomoxetine treatment~* Patients will not be included in the study if they are judged by the study investigator to be at serious suicidal risk~* Patients will not be included in the study if they have cardiovascular disease or other conditions that could be worsened by an increased heart rate or increased blood pressure

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine 0.2 milligram per kilogram per day (mg/kg/day) (Type: ACTIVE_COMPARATOR): None
- Atomoxetine 0.5 mg/kg/day (Type: ACTIVE_COMPARATOR): None
- Atomoxetine 1.2 mg/kg/day (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatments of Acquired Apraxia of Speech

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have acquired apraxia of speech that occurred following a stroke or other brain injury.~* Must be at least 6 months post-onset of brain injury.~* May have aphasia.~Exclusion Criteria:~* History of drug or alcohol abuse.~* History of mental illness.~* Neurological condition other than that which resulted in apraxia of speech.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- SPT-B then SPT-R (Type: EXPERIMENTAL): Participants first received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
- SPT-R then SPT-B (Type: EXPERIMENTAL): Participants first received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children between 1 year and 18 years of age.~* The presence of documented venous or arterial thrombosis confirmed by diagnostic imaging.~* Weight greater than 8.3 kg.~* Signed informed consent/assent.~Exclusion Criteria:~* Patients with active bleeding.~* Patients with planned invasive procedures less than 2 weeks from the time of enrollment.~* Patients with a contraindication to anticoagulation.~* Patients receiving thrombolytic agents.~* Patients with an INR\>1.5 or an activated partial thromboplastin time (PTT)\>40 seconds.~* Patients with a creatinine level above 1.2 times the upper limit of normal expected for age.~* Children \<1 year of age.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Japan Statin Treatment Against Recurrent Stroke (J-STARS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemic stroke except for cardiogenic embolism, from 1 month to 3 years after onset~* Hyperlipidemia and total cholesterol level of 180-240mg/dl without the prescription of statin within previous 30 days~* Able to visit outpatient department~* Informed consent on the form.~Exclusion Criteria:~* Ischemic stroke of other determined cause according to the TOAST classification~* Ischemic heart disease and necessary to use statin~* Hemorrhagic disorders~* Platelet count \<=100,000/ul within 3 months prior to study start~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)\>= 100IU/L within 3 months prior to study start~* Serum creatinine \>=2.0mg/dl within 3 months prior to study start~* A scheduled operation~* The presence of malignant disorder

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pravastatin (Type: ACTIVE_COMPARATOR): Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
- No intervention (Type: NO_INTERVENTION): Patient has no intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who are either inpatients or outpatients~2. Patients who have the ability to understand and to provide informed consent to the examination, observation, and evaluation processes specified in this protocol, and have signed the informed consent form based on a full understanding of the trial~3. Patients diagnosed as having either 296.2x Major Depressive Disorder, Single Episode or 296.3x Major Depressive Disorder, Recurrent according to DSM-IV-TR, and for whom the current episode of major depressive disorder has been ongoing for more than 8 weeks~4. Patients with a HAM-D17 total score of 18 or more~Exclusion Criteria:~1. Female patients of child bearing potential who wish to become pregnant during the treatment period, or within 4 weeks after study completion/discontinuation~2. Female patients who are pregnant, possibly pregnant, or breast feeding~3. Patients judged to be unable to tolerate any type of antidpressant treatment (including drugs not being used in the current episode of major depressive disorder), based on treatment history to date~4. Patients who have previously received electro-convulsive therapy~5. Patients who have participated in clinical studies on medical devices or other drugs within the past month~6. Patients at risk of having serious adverse events or developing symptoms that could interfere with safety and efficacy evaluations (such as symptoms of fibromyalgia syndrome overlapping with symptoms of depression), based on previous medical history~7. Patients with a history or a complication of diabetes~8. Patients with thyroid disease (excluding patients who are stabilized on drug therapy for at least 3 months)~9. Patients with a history of serotonin syndrome or psychotropic neuroleptic malignant syndrome~10. Patients with a history of seizure disorder (epilepsy etc.)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Fixed dose
- 2 (Type: EXPERIMENTAL): Titration dose
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with positive strongyloides larva in the stool~Exclusion Criteria:~* Pregnancy~* Lactating women~* Known allergy to any study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Albendazole (Type: ACTIVE_COMPARATOR): Albendazole for 7 days
- ivermectin (Type: EXPERIMENTAL): ivermectin 200 mcg/kg single dose
- ivermectin 2 doses (Type: EXPERIMENTAL): ivermectin 200 mcg/kg two doses in 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).~* The subject must have completed the end of treatment visit of NN1250-3643 with Insulin degludec once daily + metformin.~* Ability and willingness to adhere to the protocol including self measurement of plasma glucose according to the protocol~Exclusion Criteria:~* Participated in NN1250-3643 and treated with insulin glargine~* Previous treatment with glucacon like peptide (GLP-1) receptor agonists (e.g. exenatide, liraglutide)~* Impaired liver function, defined as alanine aminotransferase (ALAT) 2.5 times the upper limit of normal at end of treatment in NN1250-3643~* Impaired renal function defined as serum-creatinine = 125 µmol/l (= 1.4 mg/dl) for males and = 110 µmol/L (= 1.3 mg/dl) for females or according to local label for metformin \[For France: glomerular filtration rate below 60 ml/min, calculated by the Cockroft \& Gault formula\] at end of treatment in NN1250-3643.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg (non-randomised) (Type: EXPERIMENTAL): None
- IDeg + IAsp (Type: EXPERIMENTAL): None
- IDeg + liraglutide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Patients with at least 65 years-old~* Patients with essential hypertension Exclusion Criteria~* Severe hypertension~* History or evidence of a secondary form of hypertension~* History of Hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined inclusion exclusion criteria also apply.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Osteoarthritis With the Stromal Vascular Fraction of Abdominal Adipose Tissue - a Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Age 18-70 years. Kellgren-Lawrence grade 1 - 4 evaluated on x-ray or ICRS grade 2-4 evaluated on MRI.~The patient must be expected to be able to attend rehabilitation and post-examinations.~The patient must be able to speak and understand Danish. The patient must be able to give informed consent.~Exclusion Criteria:~Varus or valgus malalignment of the knee \> 5 degrees. BMI \> 35 Terminal illness or severe medical illness: ASA score higher than or equal to 3.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): All patients are recieving the treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IV Glucose for Dehydration Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females age 2 months to 12th birth date~2. Gastroenteritis (as diagnosed by ED attending or fellow physician)~3. Need for IV fluids~4. Dextrose stick of greater than 60 and less than 170~5. Parental/guardian English speaking and granting informed consent~Exclusion Criteria:~1. Underlying chronic disease affecting glucose metabolism or reason/persistence of symptoms: Renal failure, Diabetes Mellitus, Diabetes Insipidus, Metabolic Disorder, VP shunt, Migraine Headaches~2. Shock~3. Vomiting greater than 72 hours since onset of illness~4. Patients that have received IV fluids at an outside institution within 12 hours

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- 5% Dextrose (D5) in Normal Saline (NS) (Type: EXPERIMENTAL): 10cc/kg D5NS, followed by 30cc/kg NS
- Normal Saline (NS) (Type: ACTIVE_COMPARATOR): 10cc/kg NS, followed by 30cc/kg NS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxazyme in Patients With Hyperoxaluria

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Roux-en-Y gastric bypass hyperoxaluric Calcium oxalate (CaOx) stone subjects or Idiopathic hyperoxaluric CaOx stone subjects~* Patients must have or had radio-opaque stones present on x-ray, or a history consistent with the passage of a stone or stone surgery or Extracorporeal Shock Wave Lithotripsy (ESWL) in the last 5 years.~* Hyperoxaluria Ox/Cr ratio ≥36 mg/g~* The patient must be able to provide written informed consent~* Patients must be able to urinate reliably into a collection vessel to measure urine volume.~* Patients may be taking drugs for the prevention of stone disease, including pyridoxine, thiazides, citrate supplements and allopurinol, as long as there have been no changes in these medications for at least 3 months~Exclusion Criteria:~* Primary hyperoxaluria patients~* Use of Oxadrop, Oxabsorb, or other therapies affecting oxalate absorption from the gut, other than stable doses of calcium.~* Subjects who are pregnant. Women of childbearing potential must have a negative pregnancy test prior to enrollment and must practice some form of birth control during the trial.~* Patients on an unstable dose of any other drugs for the prevention of stone disease (i.e., pyridoxine, citrate supplements. etc.). Patients should have been on a stable dose for at least 3 months prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RYGB CaOx Stone Formers (Type: EXPERIMENTAL): Subjects with enteric hyperoxaluria after Roux-en-Y Gastric Bypass (RYGB).~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily.
- Idiopathic Hyperoxaluria CaOx Stone Formers (Type: EXPERIMENTAL): Subjects with idiopathic hyperoxaluria.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Foley Catheter Versus Cervidil for Induction of Labor at Term

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Cervix \< 3 cm dilated. If 2cm dilated, must be \< 80% effaced.~2. Gestational age ≥ 36 weeks by best obstetric estimate, and clinical management decision is delivery.~3. Singleton gestation~4. Cephalic presentation~Exclusion Criteria:~1. Regular uterine contractions (more frequent than every 5 minutes)~2. PROM~3. Prior transverse uterine incision or any obstetric contraindication to labor~4. Fever (defined as a temperature of 38°C or higher)~5. Lethal fetal anomalies (Labor induction is being performed, but there is no plan for fetal heart rate monitoring or cesarean delivery for fetal indications.)~6. Fetal death~7. Placenta previa~8. Suspected placental abruption or undiagnosed bleeding characterized as more than spotting~9. Non-reassuring fetal heart rate pattern~10. HIV

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- FOLEY BALLOON (Type: ACTIVE_COMPARATOR): Comparing foley balloon to cervidil for decreased time from the start of the induction process to delivery
- CERVIDIL (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female subjects who are ≥18 years of age on the day of signing informed consent.~* Diagnosis of moderate to severe ankylosing spondylitis with documented evidence of fulfilling the Modified New York (NY) criteria~* Have active ankylosing spondylitis with a BASDAI ≥4 (numeric rating scale \[NRS\] 0-10) and spinal pain ≥4 (0-10 NRS) (based on BASDAI question 2, see protocol) at screening and baseline.~* Have had a documented inadequate response to NSAIDs including cyclooxygenase-2 (COX-2) inhibitors.~* If using cDMARD therapy, stable dose for at lead 4 weeks prior to Baseline.~* If using non-drug therapies (including physical therapies), these should be kept stable during screening.~* Male and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use highly effective methods of contraception as described in the protocol.~Key Exclusion Criteria:~* Use of JAK inhibitors, investigational or approved, at any time, including filgotinib;~* Prior use of more than one TNF inhibitor, at any time.~* Use of oral steroids at a dose \>10 mg/day of prednisone or prednisone equivalent or at a dose that hasn't been stable for at least 4 weeks prior to baseline;~* Any therapy by intra-articular injections (e.g. corticosteroid, hyaluronate) within 4 weeks prior to screening;~* Use of more than 1 NSAID or COX-2 inhibitor.~* Contraindication to MRI.~* History of known or suspected complete ankylosis of the spine.~* Presence of very poor functional status or unable to perform self-care.~* Have undergone surgical treatment for ankylosing spondylitis within the last 12 weeks prior to screening.~* Administration of a live or attenuated vaccine within 12 weeks prior to baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oral filgotinib tablets (Type: EXPERIMENTAL): None
- placebo tablets (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dosing Flexibility Study in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with established adult rheumatoid arthritis currently on Methotrexate for at least 3 months~Exclusion Criteria:~* All concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment~* Previous clinical trials participation and previous biological therapy that could interfere with the results of the present clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol 400 mg and placebo (Type: ACTIVE_COMPARATOR): 400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
- Certolizumab pegol 200 mg and placebo (Type: EXPERIMENTAL): 200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered as two injections every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete